Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2

Exclusion Criteria

• •Hypersensitivity to TXA or any of the ingredients
• •Pregnancy
• •Irregular menstrual bleeding with unidentified cause
• •Acquired colour vision disturbances
• •Acute and chronic renal insufficiency indicated by GFR ≤ 30 mL/min
• •Hematuria, caused by diseases of renal parenchyma
• •Concomitant intake of hormonal contraceptives, factor IX complex concentrates, and anti-inhibitor coagulant concentrates (factor VII, activated factor IX)
• •History of angioplasty with cardiac stent placement, or cardiac (including mechanical) valve placement
• •Active history of stroke (hemorrhagic and ischemic), or subarachnoid hemorrhage, within the past 6 months
• •Consumption coagulopathy/disseminated intravascular coagulation (DIC) in the last 7 days
• •History of malignant brain tumors (glioma, metastasis and others) or seizures within the 6 months
• •Contraindication to stopping full therapeutic doses of non-ASA antiplatelets, warfarin, rivaroxaban, apixaban, dabigatran, or other anticoagulant for 2 weeks after surgery
• •Inability of oral drug intake or missing support to guarantee oral drug intake
• •SDH as caused by intracranial hypotension resulting from CSF shunt placement